Escalation restarts. A person moving to tirzepatide begins at that product’s labeled starting dosage and titrates on its own schedule, regardless of where they finished on semaglutide. There is no equivalence between the two, so the months already spent climbing do not transfer, and the phase where side effects concentrate has to be crossed again.
What the tirzepatide schedule allows
The Zepbound labeling sets a single starting point for every indication: 2.5 mg injected subcutaneously once weekly for four weeks. It states directly that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. After four weeks the dosage increases to 5 mg, and from there it may rise in 2.5 mg increments after at least four weeks on the current dose. The maintenance options for weight reduction are 5 mg, 10 mg or 15 mg. The maximum for any indication is 15 mg.
Two words in that schedule do the work. “At least” sets a floor on the interval, not a target, so a slower climb is inside the labeling while a faster one is not. And the labeling says to consider treatment response and tolerability when selecting the maintenance dosage, and to consider a lower maintenance dosage for patients who do not tolerate one. The endpoint is not fixed at the maximum.
| Step on the new product | What the labeling states |
|---|---|
| Weeks 1 to 4 | 2.5 mg once weekly, initiation only, not a maintenance dosage |
| Week 5 | Increase to 5 mg once weekly |
| Any later increase | 2.5 mg increments, after at least four weeks at the current dose |
| Maintenance, weight reduction | 5 mg, 10 mg or 15 mg once weekly |
| Maintenance, obstructive sleep apnea | 10 mg or 15 mg once weekly |
| Ceiling | 15 mg once weekly for all indications |
These are tirzepatide figures describing a tirzepatide schedule. They do not line up against semaglutide numbers, and nothing in either prescribing information invites that comparison.
Why the first weeks feel like a step backwards
Appetite suppression at an initiation dose is weaker than at a sustained maintenance dose. That is the whole reason maintenance doses exist. Someone arriving from a settled semaglutide maintenance dose is dropping to the bottom of a different range, and the difference is usually noticeable within a fortnight.
The weight trajectory often follows. Flattening, or a small move in the wrong direction during the early weeks of a transition, is the expected consequence of lower drug exposure rather than a signal that the new product does not work. Judging efficacy at an initiation dose repeats the error that frequently prompted the switch in the first place.
Setting expectations for those first weeks is easier with a reference that shows both dosing ladders in one place. The telehealth field does this inconsistently: Henry Meds, LifeMD and Hims and Hers describe their programs in their own terms, while HealthRX runs a Wegovy vs Zepbound comparison that lines the semaglutide and tirzepatide steps up against each other. Seeing that a new starting dose sits at the foot of a separate range makes the early drop in appetite suppression read as arithmetic rather than a stumble.
Tolerance does not travel with you
People assume that having survived one escalation earns credit toward the next. It does not work that way. Both labels tie their titration structure explicitly to reducing the risk of gastrointestinal adverse reactions, which means both treat the climb itself as the risk period.
The trial data agree. In SURMOUNT-5, an open-label head-to-head trial of 751 adults with obesity and without type 2 diabetes randomized to the maximum tolerated dose of tirzepatide or of semaglutide for 72 weeks, gastrointestinal events were the most common adverse events in both groups, mostly mild to moderate, and occurred primarily during dose escalation. Both arms, same pattern.
The Zepbound labeling puts numbers on the severe end. Pooled across two weight reduction trials, severe gastrointestinal adverse reactions were reported in 1.7 percent of patients at 5 mg, 2.5 percent at 10 mg and 3.1 percent at 15 mg, against 1 percent on placebo. Permanent discontinuation for adverse reactions ran at 4.8, 6.3 and 6.7 percent across those doses against 3.4 percent on placebo, and the labeling notes that most of those discontinuations happened during escalation.
Which makes escaping side effects a weak reason to move
Both molecules act on the GLP-1 receptor, both slow gastric emptying, and both produce mainly nausea, diarrhea, vomiting and constipation. Someone switching to get away from that is changing molecules within a shared mechanism and simultaneously re-entering the phase when the effects are worst. It is the one motivation that reliably makes the next three months harder than the last three.
The timeline nobody budgets for
Count it honestly. Four weeks at the initiation dose, then a minimum of four weeks at each subsequent step, means reaching 10 mg takes at least twelve weeks and 15 mg at least twenty, before any pause for a poorly tolerated step. A switch is therefore a decision to spend several months below a settled maintenance dose in exchange for an outcome that cannot be assessed until the far end.
That timeline has a financial shape as well, and it is the one most often misjudged, because introductory pricing rarely survives the escalation. Manufacturer channels such as LillyDirect and NovoCare Pharmacy price by strength, while telehealth prescribers including Ro, LifeMD, Sesame and formblends.com publish their own cash structures, and the figure that matters is the one at the dose the plan is climbing toward rather than the one at the starting dose.
Slowing the climb is a real option
Titration is not a race, and both labels build in room. The Wegovy labeling advises considering a four-week delay in escalation for patients who do not tolerate a dose. The Zepbound labeling sets a minimum interval rather than a maximum and invites a lower maintenance dosage where a higher one is not tolerated. A prescriber holding someone at 5 mg for eight weeks is following the labeling, not deviating from it.
This matters more on a switch than on a first course, because the patient has a reference point. Symptoms that would have seemed ordinary during a first escalation feel like regression when measured against a comfortable maintenance dose that ended last month.
Compounded products complicate the count
Compounded semaglutide and tirzepatide are not FDA-approved, and concentration varies between pharmacies rather than following a labeled standard. A person escalating on a compounded preparation may not have been following the approved schedule at all, so the record of what was actually taken, at what strength and from which pharmacy, is what a prescriber needs before setting a starting point on anything new.
Frequently asked questions
How long before a maintenance dose is reached?
At the labeled minimum, twelve weeks to reach 10 mg and twenty to reach 15 mg, since each step requires at least four weeks at the current dose. Any pause for tolerability extends that. Planning around three to five months rather than a few weeks is realistic.
Does tolerance built on the previous drug carry over?
Not in a way that lets escalation be shortened. Both labels tie their titration schedules to reducing gastrointestinal risk, and trial data show those events concentrating during escalation in both semaglutide and tirzepatide groups. The new schedule applies as written regardless of prior exposure.
Can escalation be slowed deliberately?
Yes, and the labeling anticipates it. The interval between increases is a minimum, not a target, and a lower maintenance dosage is an option where a higher one is not tolerated. Holding a step longer is a normal prescribing decision rather than a failure of the plan.
Why does the initiation dose feel weaker than the old maintenance dose?
Because it is a lower dose in its own range, and the labeling states that the initiation dose is not approved as a maintenance dosage. Reduced appetite suppression and a flatter weight trajectory during those first weeks reflect exposure rather than a failure of the new product.
Is a plateau on the old product a sound reason to move?
It can be, provided it is genuinely a plateau: a maintenance dose reached, held for months, and still producing no further change. A stall during escalation or after a few weeks at a starting dose is a different observation and points somewhere else.
